<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4584">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04497519</url>
  </required_header>
  <id_info>
    <org_study_id>CARRIED-01</org_study_id>
    <nct_id>NCT04497519</nct_id>
  </id_info>
  <brief_title>Local Tolerability and Pharmacokinetic Evaluation of Cyclops Dry Powder Hydroxychloroquine Inhalation in Healthy Volunteers</brief_title>
  <official_title>Local Tolerability and Pharmacokinetic Evaluation of Cyclops Dry Powder Hydroxychloroquine Inhalation in Healthy Volunteers; a Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medical Center Groningen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Medical Center Groningen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rationale:&#xD;
&#xD;
      This protocol describes a study on the local tolerability of dry powder hydroxychloroquine&#xD;
      using the Cyclops in healthy volunteers.&#xD;
&#xD;
      Objective:&#xD;
&#xD;
        -  Primary objective is to assess the local tolerability of dry powder hydroxychloroquine&#xD;
           sulphate via the Cyclops at different dosages.&#xD;
&#xD;
        -  Secondary objective is to investigate systemic pharmacokinetic parameters of dry powder&#xD;
           hydroxychloroquine sulphate via the Cyclops at different dosages.&#xD;
&#xD;
      Study design: single center, ascending dose study Study population: twelve healthy volunteers&#xD;
&#xD;
      Main study parameters/endpoints:&#xD;
&#xD;
      The local tolerability of the inhalation of dry powder hydroxychloroquine sulphate (5, 10 and&#xD;
      20 mg) defined by a lung function deterioration (a drop of forced expiratory volume in 1&#xD;
      second (FEV1) of &gt;15%), cough, or any other reported adverse event. Pharmacokinetic&#xD;
      parameters will be derived from calculated actual inhaled dose (dose minus remainder in&#xD;
      inhaler after inhalation) and in blood samples drawn pre-dose, at 0.5 and 2 and 3.5 hrs after&#xD;
      inhalation. The inspiratory parameters during the inhalation maneuver are critical to explore&#xD;
      predictors for drug exposure. The following parameters will be measured/calculated: dPmax&#xD;
      (maximum pressure drop), Vi (inhaled volume), Ti (total inhalation time), PIF (peak&#xD;
      inspiratory flow rate), MIF (mean inspiratory flow rate) and the FIR (average flow increase&#xD;
      rate between 20% and 80% of PIF).&#xD;
&#xD;
      Nature and extent of the burden and risks associated with participation, benefit and group&#xD;
      relatedness: The participants included are healthy volunteers. They will receive three&#xD;
      different doses of hydroxychloroquine sulphate using the dry powder inhaler (DPI) with (at&#xD;
      least) seven days in between doses. Before using the dry powder inhaler (DPI), they will&#xD;
      receive instructions and their inspiratory flow will be tested. To investigate local&#xD;
      tolerability, lung function tests will be performed, and the occurrence of adverse events&#xD;
      will be scored. Furthermore, before each test dose an indwelling cannula will be inserted and&#xD;
      blood samples will be taken before and after each test dose. Four blood samples will be&#xD;
      collected with each inhaled dose. Finally, five ECGs will be obtained to monitor for QT&#xD;
      prolongation, one at the screenings visit, one at base-line and one after each inhalation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 15, 2020</start_date>
  <completion_date type="Actual">November 1, 2020</completion_date>
  <primary_completion_date type="Actual">October 15, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Healthy volunteers</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Local tolerability</measure>
    <time_frame>35 minutes after inhalation</time_frame>
    <description>Number of patients with a lung function deterioration (a drop of forced expiratory volume in 1 second (FEV1) of &gt;15%.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Local tolerability</measure>
    <time_frame>95 minutes after inhalation</time_frame>
    <description>Number of patients with a lung function deterioration (a drop of forced expiratory volume in 1 second (FEV1) of &gt;15%.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Local tolerability</measure>
    <time_frame>5 hours</time_frame>
    <description>Number of patients that report cough, or any other adverse event after inhalation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameter</measure>
    <time_frame>0,5 hour</time_frame>
    <description>Calculated actual inhaled dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameter</measure>
    <time_frame>3,5 hours</time_frame>
    <description>Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameter</measure>
    <time_frame>3,5 hours</time_frame>
    <description>Tmax</description>
  </secondary_outcome>
  <enrollment type="Actual">12</enrollment>
  <condition>Covid19</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>inhaled hydroxychloroquine</intervention_name>
    <description>ascending dose of iHCQ</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy volunteer&#xD;
&#xD;
          -  Age 18-65 years&#xD;
&#xD;
          -  Obtained written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnancy or breastfeeding. Women in the fertility period and without using proper&#xD;
             contraceptives will undergo a urine pregnancy test.&#xD;
&#xD;
          2. Contra-indication to (hydroxy)chloroquine or quinine (allergic reaction, prolonged&#xD;
             QTc-interval (&gt; 450 msec), long-QT syndrome (LQTS), retinopathy, epilepsia, myasthenia&#xD;
             gravis, G6PD-deficiency).&#xD;
&#xD;
          3. Concurrent use of ciclosporin, digoxin, ritonavir, tamoxifen or tranylcypromine.&#xD;
&#xD;
          4. Concurrent use of high risk QTc prolongating drugs (amiodarone, erythromycin (daily&#xD;
             dose &gt; 1000 mg) or sotalol)16.&#xD;
&#xD;
          5. COVID-19 like symptoms, such as fever, couch, or sore throat; only by history taking.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University Medical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>July 27, 2020</study_first_submitted>
  <study_first_submitted_qc>July 31, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 4, 2020</study_first_posted>
  <last_update_submitted>November 9, 2020</last_update_submitted>
  <last_update_submitted_qc>November 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Medical Center Groningen</investigator_affiliation>
    <investigator_full_name>Onno Akkerman</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Aspiration</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydroxychloroquine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

